RecallRadar

FDA Drug recall D-1470-2016

Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada,…

On 2016-08-31 the FDA classified a Class II recall of Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada,… by Teva North America, citing superpotent drug: Out of specification test result for assay during stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1470-2016
ClassificationClass II
Statusterminated
Initiated2016-06-24
Published2016-08-31
Last updated2026-09-13 11:51 UTC
CompanyTeva North America
DistributionUS

Product

Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76

Reason

Superpotent drug: Out of specification test result for assay during stability testing.

Identifiers

ndc0093-2263-01
ndc0093-2264-01
ndc0093-4160-76
ndc0093-4160-78
ndc0093-4160-73
ndc0093-4155-79
ndc0093-4155-73
ndc0093-4155-80
ndc0093-4161-76
ndc0093-4161-78
ndc0093-4161-73
ndc0093-2267-01
ndc0093-2268-01
ndc0093-3107-01
ndc0093-3107-05
ndc0093-3109-53
ndc0093-3109-05
code_infoLot # 35434158A, Exp 6/17

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1470-2016%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.